Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,755.00
  • Today's Change8.50 / 0.49%
  • Shares traded888.30k
  • 1 Year change-37.34%
  • Beta0.6503
Data delayed at least 20 minutes, as of Nov 22 2024 04:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.

  • Revenue in JPY (TTM)484.30bn
  • Net income in JPY95.13bn
  • Incorporated1947
  • Employees3.85k
  • Location
    Ono Pharmaceutical Co Ltd1-8-2, Kyutaro-machi, Chuo-kuOSAKA-SHI 541-8564JapanJPN
  • Phone+81 662635670
  • Fax+81 662632976
  • Websitehttps://www.ono-pharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4528:TYO since
announced
Transaction
value
Deciphera Pharmaceuticals IncDeal completed29 Apr 202429 Apr 2024Deal completed-23.70%2.29bn
Data delayed at least 20 minutes, as of Nov 22 2024 04:43 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kissei Pharmaceutical Co Ltd81.07bn10.73bn182.70bn1.78k15.330.745611.962.25241.71241.711,825.834,969.030.32941.602.9845,568,860.004.383.614.753.9049.8849.4713.3112.694.15--0.005734.8711.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.87.25bn18.24bn203.74bn1.14k9.211.099.752.34481.71481.712,303.804,076.800.48641.983.8876,867,840.0010.176.8311.667.8760.6654.7820.9114.484.47--0.024351.25-1.29-5.2147.52-14.700.36390.00
Sumitomo Pharma Co Ltd342.67bn-279.46bn235.95bn4.98k--2.06--0.6886-703.41-703.41862.50287.370.35171.304.2868,808,230.00-28.68-5.07-51.21-7.7359.5669.99-81.54-12.280.424-12.100.7732---43.38-7.29-322.71--4.02--
Sawai Group Holdings Co Ltd177.34bn16.55bn255.97bn3.48k15.381.209.021.44126.61184.411,357.791,623.190.46581.122.8350,929,920.003.170.71044.240.970530.7335.086.801.471.3938.130.316988.138.04-0.824946.82-2.3318.150.00
Nippon Shinyaku Co., Ltd.154.27bn26.05bn282.27bn2.21k10.391.158.931.83386.74386.742,290.533,486.810.59561.293.3669,711,700.0010.0610.4511.3912.3167.6961.2716.8916.474.22--0.010732.622.835.2613.329.6645.9312.12
Hisamitsu Pharmaceutical Co Inc150.19bn14.65bn360.59bn2.76k21.691.1417.292.40195.20195.201,996.173,730.090.43233.013.2254,434,580.004.364.225.254.8256.4258.6210.1010.033.14--0.00453.0510.42-0.238518.97-6.1728.900.5989
Tsumura & Co164.61bn25.20bn375.12bn4.14k14.721.269.792.28331.93331.932,167.873,875.470.37830.69162.4839,781,050.006.234.817.635.8948.7650.9816.4812.653.04--0.180632.167.714.521.372.7417.545.84
Santen Pharmaceutical Co Ltd302.56bn26.13bn606.64bn3.74k22.692.0113.662.0173.4673.46846.14827.650.72382.583.6880,812,770.006.253.317.774.1057.9259.738.645.211.975.380.163982.218.225.23278.09-3.585.104.88
Rohto Pharmaceutical Co Ltd282.05bn27.26bn641.93bn7.26k22.802.4517.642.28119.22119.221,233.691,109.160.7592.184.1238,855,630.007.378.5410.2911.7957.3858.599.7110.301.29--0.144219.3913.488.0917.2825.855.2018.61
Ono Pharmaceutical Co Ltd484.30bn95.13bn870.22bn3.85k8.671.057.691.80201.26201.261,026.051,665.850.49872.373.47125,694,000.009.8011.9511.1613.7375.3874.1119.6523.892.80--0.170232.2512.4111.7313.5319.95-6.7912.20
Kyowa Kirin Co Ltd498.98bn83.53bn1.33tn5.97k16.141.5912.312.66156.64156.64936.101,591.790.48781.783.9283,524,780.008.176.289.507.0874.3075.4516.7414.963.06--0.027647.2511.0110.2551.5510.5210.289.86
Eisai Co Ltd753.22bn40.97bn1.38tn11.07k32.401.6016.681.83143.36143.362,634.812,905.110.56730.89333.8968,060,180.003.215.294.327.1679.1276.915.678.681.50--0.178174.13-0.35612.90-23.50-7.72-2.111.30
Shionogi & Co Ltd418.51bn154.57bn1.83tn4.96k11.401.3610.594.38180.74180.74489.151,519.700.2920.91892.9484,393,830.0010.6912.5711.9414.2485.7084.4336.6237.916.48--0.008826.771.973.41-12.403.382.1711.22
Data as of Nov 22 2024. Currency figures normalised to Ono Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

21.61%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 14 Apr 202324.64m4.94%
BlackRock Fund Advisorsas of 29 Mar 202416.77m3.36%
The Vanguard Group, Inc.as of 06 Nov 202414.63m2.93%
Nomura Asset Management Co., Ltd.as of 07 Nov 202414.27m2.86%
BlackRock Japan Co. Ltd.as of 29 Mar 20248.94m1.79%
Norges Bank Investment Managementas of 30 Jun 20246.63m1.33%
Nikko Asset Management Co., Ltd.as of 08 Nov 20246.50m1.30%
Daiwa Asset Management Co. Ltd.as of 31 Oct 20246.19m1.24%
Geode Capital Management LLCas of 14 Nov 20245.21m1.04%
Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 20244.01m0.80%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.